Table_1_Health-Related Quality of Life for Patients Receiving Tumor Treating Fields for Glioblastoma.docx

BackgroundTo date, there has been no large-scale, real-world study of the health-related quality of life outcomes for patients using tumor treating fields (TTFields) therapy for glioblastoma (GBM) treatment.MethodsA survey was mailed to 2,815 patients actively using TTFields for treatment of GBM in the USA (n = 2,182) and Europe (n = 633). The survey included patient-reported demographic and clinical information, as well as EuroQol’s EQ-5D-5L and visual analogue scale (EQ-VAS) overall health score.ResultsA total of 1,106 applicable patients responded to the survey (USA = 782 and Europe = 324), with a mean age of 58.6 years (SD = 12.3). The average time since diagnosis and time using TTFields were 21.5 months (SD = 25.1) and 13.5 months (SD = 13.2), respectively. Over 61% of patients had been diagnosed at least 1 year prior and 28.4% at least 2 years prior; 45 patients (4.2%) had been diagnosed at least 5 years prior. Progressed disease was reported in 307 patients, while 690 reported non-progressed disease. Regression analyses showed that GBM disease progression and older age had predictable negative associations (p ConclusionThis is the largest real-world study of patient-reported quality of life in GBM and TTFields treatment to date. It shows unsurprising negative associations between quality of life and disease progression and older age, as well as more novel, positive associations between quality of life and longer time since diagnosis and time using TTFields therapy.</p

Impact of protocolized postarrest care with targeted temperature management on the outcomes of cardiac arrest survivors without temperature management

Protocolized postarrest care that includes targeted temperature management (TTM) improves survival and neurological outcomes in cardiac arrest survivors. Whether the accumulated experience regarding the use of the protocolized approach also benefits patients who did not undergo TTM has yet to be investigated. Adults (≥18 years old) with nontraumatic cardiac arrest and who survived to intensive care unit (ICU) admission were retrospectively recruited from a single tertiary medical centre from 2006 to 2009 and 2011 to 2017. Patients were excluded if they had traumatic injuries, were pregnant, did not survive to ICU admission, regained clear consciousness within 3 h after the return of spontaneous circulation, or underwent TTM. The sum of TTM cases since 2006 and before the cardiac arrest of each enrolled patient was used as a substitute index for the amount of experience accumulated from the use of protocolized TTM care. In total, 802 non-TTM patients were enrolled in the final analysis. The rate of survival to hospital discharge increased from 25.9% in 2006 to 33.3% in 2017. Regarding neurological recovery at hospital discharge, the incidence of favourable neurological function (cerebral performance category: 1 or 2) increased from 10.3% in 2006 to 23.5% in 2017. A multiple logistic regression indicated a significant association between the cumulative TTM case numbers and neurological outcomes in patients who did not receive TTM. The improvement of neurological outcomes in adult nontraumatic cardiac arrest survivors who did not receive TTM was associated with the cumulative number of cases receiving protocolized TTM care. In the era of TTM, the use of only historical control data might lead to bias, which is caused by overlooking the influence of a more refined protocolized postarrest care that includes TTM.KEY MESSAGEThe cumulative number of cases receiving protocolized TTM care, which we used as a substitute index for the amount of experience accumulated from the use of protocolized postarrest care that includes TTM, was associated with the improvement of neurological outcomes in adult nontraumatic cardiac arrest survivors who did not receive TTM. The cumulative number of cases receiving protocolized TTM care, which we used as a substitute index for the amount of experience accumulated from the use of protocolized postarrest care that includes TTM, was associated with the improvement of neurological outcomes in adult nontraumatic cardiac arrest survivors who did not receive TTM.</p

Additional file 6 of A flexible liposomal polymer complex as a platform of specific and regulable immune regulation for individual cancer immunotherapy

Additional file 6. RNA-seq analysis of theimmunomodulation activities by LPPC/MP complex with different antibodies. (A) Volcano plot for gene expression and the FC values of genes. (B) Pie chart demonstrating the proportionof mouse RNA-seq reads assigned to annotated genomic functions

Additional file 3 of A flexible liposomal polymer complex as a platform of specific and regulable immune regulation for individual cancer immunotherapy

Additional file 3. The activities of LPPC/MP complexes. The splenocytes from different treatments were pulsed with BSA antigens, and the cytokines secretion were estimated at different times by ELISA, such as IFN-γ (A) and IL-4 (B). Each data indicated the mean ± SD from three independent experiments (N=6)

Additional file 5 of A flexible liposomal polymer complex as a platform of specific and regulable immune regulation for individual cancer immunotherapy

Additional file 5. Flow chart of theprocess for RNA-seq analysis. The flow chart described how RNA data wereprocessed, the criteria for every stage, and the number of genes. The number ofupregulation genes was shown in red, while that of downregulation genes wasshown in blue

Additional file 4 of A flexible liposomal polymer complex as a platform of specific and regulable immune regulation for individual cancer immunotherapy

Additional file 4. The lung photos of mice under different treatments. (A)The representative photos of the lungs from differenttreatments of Fig. 7B were selected. (B) The representative photos ofthe lungs from different treatment groups of Fig. 8B were selected

Additional file 2 of A flexible liposomal polymer complex as a platform of specific and regulable immune regulation for individual cancer immunotherapy

Additional file 2. The effects of LPPC/Abcomplexes on the cell cycle. The cell cycle profiles ofnaive (A) or activated (B) splenocytes under LPPC/Ab complexestreatments were performed by PI staining. A significant difference compared tothe LPPC/CD3 group was indicated by * (P<0.05)

Additional file 1 of A flexible liposomal polymer complex as a platform of specific and regulable immune regulation for individual cancer immunotherapy

Additional file 1. Construction of LPPC/MP andLPPC/MP/Ab complexes.The picture illustrated the formulation of LPPC complexes with different immunofunctionalproteins and their specific aims

Additional file 7 of A flexible liposomal polymer complex as a platform of specific and regulable immune regulation for individual cancer immunotherapy

Additional file 7. RNA-seq analysis of the immunomodulation activitiesby LPPC/MP complex with different antibodies. The RNA expression levels of immunecells under different treatments were determined by t-tests and ANOVA,and the results were shownas boxplots. The description of group names was the same as in Fig. 9